Home / Market News / $SCNX
benzinga Corporate Catalyst Impact 75/100 ● positive

EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US

Aug 12, 2026, 11:46 AM UTC · Primary ticker $SCNX

Scienture Holdings has officially launched Rezenopy, a 10mg naloxone nasal spray, across the U.S., fulfilling initial purchase orders. This marks a significant commercial milestone for the company, as Rezenopy is the highest-dose naloxone spray available and targets the growing market for high-potency synthetic opioid overdoses, potentially driving revenue growth.

Scienture Holdings (SCNX) has announced the commercial rollout of Rezenopy, its 10mg naloxone nasal spray, which is the highest-dose product of its kind on the market. This is a significant positive catalyst for SCNX as it represents the nationwide distribution of its second FDA-approved product and positions the company to capture a substantial share of the growing domestic naloxone market, especially given its strategic sales force and institutional access agreements. The short-term implication is potential revenue generation from initial sales, while the long-term implication is sustained growth towards anticipated profitability in 2027. The key opportunity for traders is the potential for increased stock valuation as the product gains market traction, though initial premarket trading showed a slight dip, suggesting market skepticism or profit-taking.

$SCNX positive Product launch and commercialization
$KNDV neutral Partner in manufacturing
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.